Explore how commercial determinants shape health outcomes and the need for systemic change in public health policy.
Eton Pharmaceuticals. Eton Pharmaceuticals expands rare disease portfolio through acquisition of U.S. commercialization rights to HEMANGEOL® (propranolol hydrochloride) oral solution. Eton ...
Recent transactions make clear that large pharmaceutical companies now view rare disease as a core area for sustained growth, rather than episodic deal-making. BioMarin’s acquisition of Amicus ...
ANI Pharmaceuticals (ANIP) reported Q4 revenue of $247.1M, up 29.6%, driven by Cortrophin and ILUVIEN. 2026 guidance targets $1.06–$1.12B in revenue.
Rare Disease Day is held on the last day of February to raise awareness for rare diseases and address drug development ...
As Rare Disease Day approaches, the lessons from recent European launches are clear: success comes from disciplined operating models, disease‑centred engagement, pragmatic evidence strategies, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results